Targeting the EGFR Pathway in Preclinical Oncology Studies

Several therapeutic advances have been made targeting EGFR (epidermal growth factor receptor) and its family members. EGFR is easily accessible given its location on the cell surface as a transmembrane glycoprotein. Once the receptor is conjugated with the EGF ligand, it induces the activation of a complex signaling cascade that plays a role in a variety of cellular functions. However, this pathway is also well known to be involved in tumorigenesis, most notably lung and breast cancers. Thus, the EGFR family has emerged as useful biomarkers of cancer and as direct therapeutic targets.

MI Bioresearch has characterized the EGFR expression of several human xenograft models. These data provide not only an assessment of the overall expression of each of the four unique dimers but also in vivo growth kinetics and response data to clinically used standard of care agents.

Below is a subset of our data that can help you begin to decide which EGFR-expressing model is right for your study. More data for other EGFR-expressing tumor models is also available upon request.

Historical Expression Data (subset):

 

Example Drill Down:

A431: Human Epidermoid Carcinoma:

Approved Standard of Care:

 

Contact our scientists to see more data and plan your next EGFR-targeting preclinical study!

 

Data from MI Bioresearch internal research and development program.